BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8256799)

  • 1. Formation-stimulating regimens other than sodium fluoride.
    Riggs BL
    Am J Med; 1993 Nov; 95(5A):62S-68S. PubMed ID: 8256799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis.
    Augustine M; Horwitz MJ
    Curr Osteoporos Rep; 2013 Dec; 11(4):400-6. PubMed ID: 24078470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anabolic therapy of osteoporosis].
    Fernández-García D; Alonso G; Muñoz-Torres M
    Med Clin (Barc); 2005 Sep; 125(9):341-5. PubMed ID: 16185635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New anabolic agents in the treatment of osteoporosis.
    Hough S
    S Afr Med J; 2003 Oct; 93(10):754-6. PubMed ID: 14652963
    [No Abstract]   [Full Text] [Related]  

  • 6. [Male osteoporosis: current treatments and future options].
    Romagnoli E; Paglia F; Dionisi S; De Geronimo S; Pepe J; Di Virgilio R; Minisola S
    Clin Ter; 2003; 154(1):49-53. PubMed ID: 12854284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Human parathyroid hormone (1-34) as a new therapeutic agent for osteoporosis].
    Isogai Y
    Clin Calcium; 2005 Jan; 15(1):18-24. PubMed ID: 15632468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anabolic activity of parathyroid hormone: a new therapeutic perspective in primary osteoporosis].
    Fiore CE; Tamburino G
    Ann Ital Med Int; 1987; 2(4):321-6. PubMed ID: 3079455
    [No Abstract]   [Full Text] [Related]  

  • 9. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets.
    Marie PJ; Kassem M
    Eur J Endocrinol; 2011 Jul; 165(1):1-10. PubMed ID: 21543379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of parathyroid hormone in the management of osteoporosis.
    Rosen CJ
    Horm Res; 2005; 64 Suppl 2():81-5. PubMed ID: 16286779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anabolic effects of intermittent PTH on osteoblasts.
    Greenfield EM
    Curr Mol Pharmacol; 2012 Jun; 5(2):127-34. PubMed ID: 21787293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats.
    Yang Y; Aghazadeh-Habashi A; Panahifar A; Wu Y; Bhandari KH; Doschak MR
    Drug Deliv Transl Res; 2017 Aug; 7(4):482-496. PubMed ID: 28721611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent Fugu parathyroid hormone 1 (1-34) is an anabolic bone agent in young male rats and osteopenic ovariectomized rats.
    McManus JF; Davey RA; Maclean HE; Doust EA; Chiu WS; Sims NA; Bouxsein ML; Glatt V; Zajac JD; Danks JA
    Bone; 2008 Jun; 42(6):1164-74. PubMed ID: 18387351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis.
    Whitfield JF; Morley P
    Trends Pharmacol Sci; 1995 Nov; 16(11):382-6. PubMed ID: 8578607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of old-age osteoporosis].
    Münzenberg KJ
    Dtsch Med Wochenschr; 1977 Aug; 102(33):1186, 1193-6. PubMed ID: 330133
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anabolic therapy of osteoporosis].
    Okopień B; Krysiak R; Labuzek K; Herman ZS
    Pol Merkur Lekarski; 2005 Jul; 19(109):118-21. PubMed ID: 16194044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New anabolic therapies in osteoporosis.
    Rubin MR; Bilezikian JP
    Curr Opin Rheumatol; 2002 Jul; 14(4):433-40. PubMed ID: 12118181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroid hormone as an anabolic therapy for women and men.
    Bilezikian JP; Rubin MR; Finkelstein JS
    J Endocrinol Invest; 2005; 28(8 Suppl):41-9. PubMed ID: 16329201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis.
    Reeve J; Arlot M; Price TR; Edouard C; Hesp R; Hulme P; Ashby JP; Zanelli JM; Green JR; Tellez M
    Eur J Clin Invest; 1987 Oct; 17(5):421-8. PubMed ID: 3121346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current research in therapy of postmenopausal osteoporosis (author's transl)].
    Laroche C; Detilleux M; Sereni D
    Sem Hop; 1979 Feb 18-25; 55(7-8):325-9. PubMed ID: 220722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.